

1 Personalized structural biology reveals the molecular mechanisms underlying 2 heterogeneous epileptic phenotypes caused by *de novo* KCNC2 variants

3 4 Authors

5 Souhrid Mukherjee^{1,6}, Thomas A. Cassini^{11,#}, Ningning Hu^{8,9,#}, Tao Yang^{5,#}, Bian Li^{1,5,6,#},
6 Wangzhen Shen⁸, Christopher W. Moth⁶, David C. Rinker^{4,6}, Jonathan H. Sheehan^{6,10}, Joy D.
7 Cogan², Undiagnosed Diseases Network, John H. Newman³, Rizwan Hamid², Robert L.
8 Macdonald^{5,8}, Dan M. Roden^{5,7,15}, Jens Meiler^{4,5,6,7,12,13,14}, Georg Kuenze^{4,6,12*}, John A. Phillips
9 III^{2*}, John A. Capra^{1,6,7,15,16*}

10
11 ¹Department of Biological Sciences, Vanderbilt University, Nashville, TN 37235, USA.

12 ²Department of Pediatrics, Division of Medical Genetics and Genomic Medicine, Vanderbilt University School of
13 Medicine, Nashville, TN 37232, USA.

14 ³Pulmonary Hypertension Center, Division of Allergy, Pulmonary and Critical Care Medicine, Vanderbilt University
15 Medical Center, Nashville, TN 37232, USA.

16 ⁴Department of Chemistry, Vanderbilt University, Nashville, TN 37235, USA.

17 ⁵Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN
18 37232, USA.

19 ⁶Center for Structural Biology, Vanderbilt University, Nashville, TN 37235, USA.

20 ⁷Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, TN 37232, USA.

21 ⁸Department of Neurology, Vanderbilt University Medical Center, Nashville, TN 37232, USA.

22 ⁹Department of Genetic Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA.

23 ¹⁰John T. Milliken Department of Internal Medicine, Washington University School of Medicine, St. Louis MO, 63110,
24 USA.

25 ¹¹Department of Internal Medicine, National Institutes of Health Clinical Center, Bethesda, MD 20814, USA.

26 ¹²Institute for Drug Discovery, Leipzig University Medical School, Leipzig, SAC 04103, Germany.

27 ¹³Department of Chemistry, Leipzig University, Leipzig, SAC 04109, Germany.

28 ¹⁴Department of Computer Science, Leipzig University, Leipzig, SAC 04109, Germany.

29 ¹⁵Vanderbilt Genetics Institute, Vanderbilt University Medical Center, Nashville, TN 37232, USA.

30 ¹⁶Bakar Computational Health Sciences Institute and Department of Epidemiology and Biostatistics, University of
31 California, San Francisco, CA 94143, USA.

32
33 # Equal contribution

34 * Correspondence: georg.kuenze@uni-leipzig.de, john.a.phillips@vumc.org, tony@capralab.org

35 36 Keywords

37 developmental and epileptic encephalopathy (DEE), KCNC2, *de novo* variant, molecular
38 dynamics (MD) simulations, electrophysiology, personalized structural biology

52

53

54 **ABSTRACT**

55 *Background.* Next-generation whole exome sequencing (WES) is ubiquitous as an early step in
56 the diagnosis of rare diseases and the interpretation of variants of unknown significance (VUS).
57 Developmental and epileptic encephalopathies (DEE) are a group of rare devastating
58 epilepsies, many of which have unknown causes. Increasing WES in the clinic has identified
59 several rare monogenic DEEs caused by ion channel variants. However, WES often fails to
60 provide actionable insight, due to the challenges of proposing functional hypotheses for
61 candidate variants. Here, we describe a “personalized structural biology” (PSB) approach that
62 addresses this challenge by leveraging recent innovations in the determination and analysis of
63 protein 3D structures.

64 *Results.* We illustrate the power of the PSB approach in an individual from the Undiagnosed
65 Diseases Network (UDN) with DEE symptoms who has a novel *de novo* VUS in *KCNC2*
66 (p.V469L), the gene that encodes the Kv3.2 voltage-gated potassium channel. A nearby *KCNC2*
67 variant (p.V471L) was recently suggested to cause DEE-like phenotypes. We find that both
68 variants are located in the conserved hinge region of the S6 helix and likely to affect protein
69 function. However, despite their proximity, computational structural modeling suggests that the
70 V469L variant is likely to sterically block the channel pore, while the V471L variant is likely to
71 stabilize the open state. Biochemical and electrophysiological analyses demonstrate
72 heterogeneous loss-of-function and gain-of-function effects, respectively, as well as differential
73 inhibition in response to 4-aminopyridine (4-AP) treatment. Using computational structural
74 modeling and molecular dynamics simulations, we illustrate that the pore of the V469L variant is
75 more constricted increasing the energetic barrier for K⁺ permeation, whereas the V471L variant
76 stabilizes the open conformation

77 *Conclusions.* Our results implicate *KCNC2* as a causative gene for DEE and guided the
78 interpretation of a UDN case. They further delineate the molecular basis for the heterogeneous
79 clinical phenotypes resulting from two proximal pathogenic variants. This demonstrates how the
80 PSB approach can provide an analytical framework for individualized hypothesis-driven
81 interpretation of protein-coding VUS suspected to contribute to disease.

82

83 **INTRODUCTION**

84 The advent of cheaper and more accurate DNA sequencing technologies has enabled the
85 integration of genetic information into diverse areas of medicine. For example, more than 70%
86 of rare diseases are thought to have a genetic cause, and recent efforts have identified the
87 causal variants for thousands of Mendelian diseases¹⁻³. However, causal variants have not
88 been identified for approximately half (~3000) of known rare genetic diseases⁴⁻⁶, and
89 sequencing often fails to lead to actionable insights, even after expert clinical evaluation through
90 programs like the NIH’s Undiagnosed Diseases Network (UDN)⁷⁻⁹.

91 Many computational methods have been developed for interpreting variants observed in
92 clinical sequencing¹⁰⁻¹³. However, they have substantial weaknesses and often disagree¹⁴⁻¹⁸.
93 In particular, commonly used tools provide only ill-defined, categorical variant classifications like
94 “pathogenic” and “benign” and fail to propose specific hypotheses about the underlying
95 molecular effects of variants. A prediction that a variant is “pathogenic” is not of much clinical

96 use without a testable prediction of the mechanisms of its pathogenicity, pleiotropic effects and
97 possible insights to treatment.

98 Motivated by the challenges of variant interpretation, recent advances in experimental
99 approaches for protein structure determination^{19–24} and recent improvements to the accuracy of
100 prediction, modeling and analysis of native 3D protein structural models^{25–28}, we propose a new
101 variant interpretation paradigm. Our “personalized structural biology” approach focuses on
102 making mechanistic predictions about the effects of the variant(s) observed in patients in the
103 context of their genetic background via computational and experimental evaluation of protein
104 structure and function. We demonstrate the power of this approach on two candidate VUS in
105 *KCNC2*, the gene encoding the homo-tetrameric voltage gated potassium channel Kv3.2, one
106 variant from an individual with an unsolved epilepsy-like disease enrolled in the UDN and
107 another variant from a recent case report²⁹ with epilepsy-like phenotypes; however no
108 functional validation was done for the variant.

109 Developmental epileptic encephalopathies (DEE) are a group of devastating disorders in
110 which epileptic activity contributes to cognitive and behavior impairment in addition to underlying
111 developmental pathologies^{30,31}. Genetic etiologies are thought to be the cause of a substantial
112 proportion of these DEE cases, and with recent advances in genetic testing technology, many
113 DEE variants have been discovered. The underlying genetic mechanisms are diverse³², but
114 defects in neuronal ion channels are thought to be a common cause of DEE. For example, the
115 initial discovery that Dravet syndrome is caused by variants in *SCN1A*³³ has been followed by
116 the demonstration that variants in many voltage-gated potassium (Kv) channels can cause
117 DEE³⁴. The largest family of these channels is the Kv family, with 12 subfamilies whose alpha
118 subunits are encoded by approximately 40 genes. The Kv3 subfamily influences rapid firing of
119 inhibitory interneurons in the central nervous system³⁵. The general mechanism of Kv3.2
120 channel gating is thought to be similar to other closely related voltage-gated potassium ion
121 channels. Kv channels consist of four homologous subunits, with each monomer having six
122 transmembrane helical domains (S1-S6). S1-S4 form the voltage sensing domain (VSD) and
123 S5-S6 from all four subunits form the membrane pore. A linker domain between S4 and S5
124 connects the VSD to the pore forming units^{36–40}. The VSD undergoes conformational changes
125 between the open and closed state of the channel⁴¹, and the coupling between the S4-S5 linker
126 and the S6 pore forming unit is responsible for the voltage dependent gating of the channel^{42,43}.
127 With a pronounced inward movement of the positively charged S4 voltage sensor, the S4-S5
128 linker is pushed downwards, which causes the S6 helix to constrict the pore, thus closing the
129 channel³⁹. This gating mechanism is made possible by the presence of a Proline-Valine-Proline
130 (PVP) motif, which acts as a hinge domain in the S6 helix. The hinge domain allows the S6
131 pore-forming helix to kink at the flexible PVP motif to open and close the channel pore.

132 Other members of this subfamily have been implicated as a potential causes of DEE and
133 other epilepsy-like symptoms with discoveries of variants in genes encoding Kv3.1 and Kv3.3^{44–}
134⁴⁶. More recently variants in *KCNC2*, which is highly expressed in GABAergic interneurons in
135 the CNS, have been suggested to be linked to DEE-like phenotypes, with possibly dominant
136 negative effects^{29,47,48}. However, the links and their mechanisms are yet to be established.

137 Our work makes four main contributions. First, we demonstrate via expression and
138 electrophysiology analyses that the two candidate *KCNC2* variants (p.V469L, p.V471L) have
139 loss-of-function and gain-of-function effects, respectively, despite both affecting the essential

140 hinge region of Kv3.2 responsible for channel gating. Second, our protein structural modeling
141 and molecular dynamics simulations rationalize the mechanistic basis for the phenotypic
142 heterogeneity of these variants. Third, our results combine to validate links between *KCNC2*
143 variants and heterogenous DEE phenotypes. Finally, our analyses provide a blueprint for
144 integrating genetics, expression analysis, electrophysiology, and protein structural modeling to
145 develop mechanistic understanding of the molecular effects of *de novo* variants in rare disease.

146 147 **RESULTS**

148 149 ***Undiagnosed Diseases Network patient with DEE-like symptoms***

150 A child (3-8 years old) at the Vanderbilt University UDN site presented with DEE-like
151 phenotypes, including multiple types of refractory seizure and global developmental delay. At a
152 very young age, they developed generalized tonic clonic seizures, and was diagnosed with
153 Lennox-Gastaut syndrome, a severe form of DEE. However, they continued to have frequent
154 myoclonic absence seizures and occasional generalized tonic clonic seizure. The IRB of the
155 National Institutes of Health (NIH) gave ethical approval for this work (protocol 15HG0130). The
156 participants' or their legal representatives' have consented to IRB 15HG0130 and allowed the
157 results of this research work to be published. A full clinical report is available upon contacting
158 the corresponding authors.

159 Initial sequencing of the individual on an epilepsy gene panel through Athena covered
160 *ARHGEF9, ARX, CDKL5, CNTNAP2, FOXG1, GABRG2, GRIN2A, KCNT1, MECP2, NRXN1,*
161 *PCDH19, PNKP, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, SCN1A, SCN1B, SCN2A,*
162 *SCN8A, SCN9A, SLC25A22, SLC2A1, SLC9AC, SPTAN1, STXBP1, SYNGAP1, TCF4,*
163 *TREX1, UBE3A, ZEB2.* The only potentially significant finding was a heterozygous c.2985G>C
164 variant in *GRIN2A*. Deletion analysis of *SCN1A* was negative as well. Secondary findings,
165 metabolic screens, and mitochondrial DNA sequencing were also negative.

166 Following the negative epilepsy panel result, WES revealed a candidate variant in a
167 voltage-gated potassium channel Kv3.2, *KCNC2* c.1405G>T (p.V469L). Sanger sequencing
168 confirmed this variant. This variant was not seen in either of his parents, and therefore it was
169 presumed to be *de novo*. This variant is in the conserved hinge motif of the channel which is
170 critical for channel gating (**Figure 1**). The potential relevance of this variant is supported by
171 another recently reported discovered candidate heterozygous variant also located in the hinge
172 domain of *KCNC2* (c.1411G>C, p.V471L) only two amino acids away from V469L variant found
173 in our UDN subject²⁹. Our UDN subject and the previously reported case shared the
174 phenotypes of DEE, seizures refractory to medications, developmental delay, and microcephaly.
175 However, their phenotypes differed in that the reported case also had complete absence of
176 speech, dystonia, decreased myelination around frontal and occipital horns of the lateral
177 ventricles, spastic tetraplegia, myoclonic jerks, and opisthotonos attacks.

178 To evaluate the evidence for these VUS and propose specific functional hypotheses, we
179 assessed the effects of these variants on protein expression, structure, and function with
180 experimental and computational methods.

181 182 ***Structural modeling suggests distinct functional effects for candidate KCNC2 variants***

183 To evaluate the potential effects of the *KCNC2* variants at the molecular level, we constructed a
184 homology model of its tetrameric structure based on a high-resolution structure of the Kv1.2-
185 Kv2.1 paddle chimera channel (PDB ID: 2R9R)⁴² using the Rosetta molecular modeling suite
186 (Methods)⁴⁹.

187 The homo-tetrameric Kv3.2 model, with six transmembrane helical domains (S1-S6) is
188 shown in **Figure 1A**. The PVP motif ranges between residues 468 and 470 on the S6 helix and
189 facilitates channel gating. The variants of interest p.V469L and p.V471L are adjacent to the PVP
190 motif (**Figure 1B**). The channel pore is formed by the S5 and S6 helices of all four chains
191 together (**Figure 1C**), and the PVP motifs on all four helices act together for channel gating.
192 This region is almost entirely conserved among vertebrates (**Figure S1A**). Furthermore,
193 previous studies have shown that altering the central hydrophobic residues in Kv1.1 channels
194 from valine to isoleucine affects channel kinetics, stability, and conformational dynamics⁵⁰.

195 The UDN subject's variant (p.V469L) results in a conservative substitution, which
196 changes the hydrophobic valine at the core of the PVP motif to leucine, another hydrophobic
197 amino acid. However, the p.V469L variant is predicted to have a deleterious effect on the
198 protein by commonly used variant effect prediction tools like CADD and GERP (**Figure S1B**).
199 The residue at position 469 faces into the channel pore (**Figure 1D**), and while conservative
200 amino acid substitutions do not usually have severe effects, in this case, the bulkier leucine
201 amino acid (**Figure 1E**) at the center of the PVP motif on the hinge domain could influence ion
202 transfer. We hypothesize that it could sterically obstruct the pore resulting in a decreased pore
203 radius and slower kinetics of channel gating. The steric hindrance of the curving of the S6 helix
204 could lead to fewer ions passing through the pore.

205 The second recently reported candidate *KCNC2* variant²⁹ (p.V471L) is immediately
206 adjacent to the PVP motif (**Figure 1A**); however, the structural context of this variant in our
207 model suggests potentially different effects from that of our UDN subject's p.V469L variant.
208 Residue p.V471 faces away from the pore (**Figure 1D**), and therefore, the substitution of the
209 bulkier amino acid leucine (**Figure 1E**) is less likely to lead to a decrease in the pore radius as
210 the residue faces outward. In this case, we hypothesize that the molecular effect of the p.V471L
211 variant would widen the pore and increase its tendency to remain open, leading to more ions
212 passing through than normal and thus a gain-of-function phenotype. We also predict that the
213 channel gating will be affected by the bulkier leucine residue; however, not to the extent of the
214 p.V469L variant since p.V471L faces away from the channel pore.

215

216 **V469L causes loss of channel function, while V471L causes gain of function**

217 To quantify the effects of the candidate variants we quantified the electrophysiological function
218 of Kv3.2, potassium channel currents for WT Kv3.2 and the two disease causing variants
219 (p.V469L and p.V471L) in CHO cells. The proteins were expressed in a homo-tetrameric model,
220 with all four chains carrying the variant, in each case. The WT form of Kv3.2 showed a very fast
221 deactivation, in accordance with previously characterized behavior of the Kv3.2 channel (**Figure**
222 **2A, S2**). *KCNC2* is primarily expressed in the brain, where its product Kv3.2 contributes to the
223 fast repolarization of action potentials in neurons of the central nervous system^{35,51,52}.

224 Therefore, short spike duration and rapid deactivation of Kv3.2 channels are important for
225 normal physiology.

226 The electrophysiological profiles for the p.V469L variant (**Figure 2B, S2**) compared to
227 the WT Kv3.2 had a lower peak current and much longer deactivation tails. The peak current for
228 the p.V469L mutant was less than half that of WT (**Figure 2D**), with a much slower deactivation
229 and a slight negative shift of ~10mV (**Figure 2E**). In contrast, the electrophysiological profile for
230 p.V471L (**Figure 2C, S2**) showed a much higher peak current than WT, with a longer
231 deactivation tail. The p.V471L peak current was 1.5 times that of the WT channel (**Figure 2D**),
232 with a moderately slower deactivation, but a drastic negative shift of ~28mV (**Figure 2E**). The
233 very slow deactivation and slightly negative voltage shift observed for p.V469L and moderately
234 slow deactivation and dramatically negative voltage shift for p.V471L align with the structural
235 hypothesis of loss-of-function and gain-of-function phenotypes, respectively. For each variant,
236 the same amount of plasmid was injected, and the behavior of the proteins at their native levels
237 of expression was analyzed.

238 We further characterized the effect of the variants on channel function by administration
239 of the voltage-gated potassium channel blocker 4-aminopyridine (4-AP). Kv3.2 is very sensitive
240 to 4-AP⁵³⁻⁵⁵. 4-AP is known to approach the channel lumen from the cytoplasmic side^{53,56,57};
241 and bind the open channel weakly. Once bound, the channel becomes biased towards the
242 closed state⁵⁶, and 4-AP binds strongly to the closed conformation, blocking the channel.

243 Interestingly, 4-AP blocked the channel activity similarly for the WT and p.V469L Kv3.2
244 (**Figure 2F, S3**). Both experienced >70% decreases in activity ($p > 0.05$, $n=6$). In contrast, the
245 gain-of-function p.V471L variant was resistant to 4-AP compared to WT and p.V469L ($p <$
246 0.0001 for both, $n=6$), showing a less than 30% reduction in activity (**Figure 2F, S3**). This could
247 be due to the V471L variant stabilizing the channel in the open conformation, thereby making 4-
248 AP less effective in closing the channel and less likely to bind. These results further support the
249 contrasting loss- and gain-of-function mechanisms we propose for p.V469L and p.V471L.

250

251 **V469L expression is lower while V471L expression is higher than wild type**

252 Rare pathogenic protein-coding variants, in addition to causing changes to protein structure and
253 molecular function, can also lead to altered protein expression in cells. We compared the levels
254 of protein present in cells for the WT and two Kv3.2 variants with an Immunoblot analysis
255 (Western Blot).

256 The homomeric V469L Kv3.2 was present at less than half the amount for homomeric
257 WT, while the levels for homomeric V471L Kv3.2 were greater than one and a half times that of
258 WT (**Figure 3**). Thus, expression differences likely contribute to the loss- and gain-of-function
259 effects for the two variants, respectively. However, while the expression levels could cause the
260 observed differences in the peak currents for the two variants (**Figure 2**), differences in protein
261 levels alone cannot explain the slowed deactivation dynamics of the V469L channel. Thus, both
262 differences in the molecular function and expression levels of these *KCNC2* variants contribute
263 to their phenotypic effects.

264

265 **V469L constricts the channel pore in molecular dynamics simulations increasing the 266 energetic barrier for K⁺ ion permeation**

267 To explore the molecular basis for the functional changes caused by V469L and V471L, we
268 performed molecular dynamics simulations of these ion channel variants and of WT Kv3.2 in
269 POPC membranes. Each system was simulated for more than 1 μ s in total. **Figure 4A-C**

270 displays simulation snapshots of the three ion channel systems and **Videos V1-V6** show
271 representative MD trajectories. We observed that the inner pore helices in V469L moved closer
272 together at their hinge motif sites such that the pore became more constricted and fewer water
273 molecules were able to enter the inner channel cavity through the cytosolic gate. This effect was
274 most likely driven by increased attractive interactions between leucine 469 residues on adjacent
275 and opposite S6 helices that led to a ‘de-wetting’ of the channel pore. Calculation of the pore
276 radius along the channel axis (z-axis) (**Figure 4D**) confirmed that the K⁺ ion permeation
277 pathway in the V469L channel is more constricted compared to WT and V471L Kv3.2 channels.

278 Furthermore, we noticed small but distinct differences of the backbone structure at
279 residue 469 and preceding residues (**Figure S4, Table T1**). By contrast, the pore radius of the
280 V471L channel was slightly wider than that of WT Kv3.2 indicating that V471L adopted a stable
281 open conformation in MD. One possible explanation for this observation is the difference in the
282 types of interactions made by residues at positions 469 and 471. While L469 side chains are
283 oriented towards each other and towards the pore, L471 residues are oriented outward and
284 interact with residues on S5 in the same subunit and with residues on S6 in a neighboring
285 subunit. The largest number of atom contacts of L471 are made with Y480 on an adjacent S6
286 helix (**Figure S5**). In the variant, the number of heteroatom contacts (within 4Å radius) for the
287 L471-Y480 interaction more than doubled relative to the V471-Y480 interaction in WT Kv3.2
288 (average of ~3.2 contacts in WT Kv3.2 to ~7.0 contacts in the V471L channel). This finding
289 offers a plausible explanation for how this amino acid change at position 471 leads to
290 stabilization of the open channel conformation.

291 To assess the energetic cost more directly for K⁺ ion permeation in WT Kv3.2 and both
292 channel variants, we used umbrella MD simulations and calculated the potential of mean force
293 (PMF) for moving a K⁺ ion from the cytosolic site of the channel through the S6 helix gate into
294 the water-filled cavity below the selectivity filter (**Figure 5A**). Compared to WT, the energetic
295 barrier for ion transfer of the V469L variant increased by ~0.8 kcal/mol (**Figure 5B**). The V471L
296 variant, however, required an energy for ion transfer similar to WT. The highest peak in the PMF
297 and the V469L-specific energy increase occurred at position P470. This indicates that V469L,
298 but not V471L, constricts the channel pore at the PVP hinge region, which is in line with our
299 pore radius measurements.

300 In summary, MD simulations provided detailed insight into the molecular mechanism
301 underlying the altered function of both variants. Our MD results agree well with the
302 experimentally observed loss-of-function and gain-of-function phenotypes for V469L and V471L,
303 respectively.

304 305 **DISCUSSION**

306 Deriving actionable information for patient diagnosis and treatment from clinical sequencing
307 data is a fundamental challenge in genetics and medicine. Current methods for analyzing
308 sequencing data often fail due to the inability to predict the effects of the detected VUS on
309 protein function. Here, we illustrate the power of a “personalized structural biology” pipeline that
310 places candidate VUS into 3D structural models tailored to the patient. The integration of cycles
311 of computational and experimental analysis enabled us to provide mechanistic molecular
312 insights into the different mechanisms by which two proximal candidate *KCNC2* VUSs lead to
313 DEE-like phenotypes. DEE has been previously linked to dysfunction of other ion channels^{58,59}.

314 Moreover, Kv3 channel family members have been previously associated with neurological
315 disorders such as ataxias, epilepsies, schizophrenia, and Alzheimer's disease⁶⁰.

316 The V469L variant occupies the central hydrophobic residue of the PVP motif and the
317 flexibility of this hinge region is critical for channel opening and closing kinetics⁶¹. Previous
318 studies in other channels supported this hypothesis, as altering the central hydrophobic
319 residues in Kv1.1 channels from valine to isoleucine, a constitutional isomer of leucine, affected
320 channel kinetics, stability, and conformational dynamics⁵⁰. The V469L variant resulted in > 50%
321 decrease in peak current and a very slow deactivation with a slight negative shift (~10mV).
322 Interestingly, the V469L variant caused the Kv3.2 channel to be expressed at < 50% of WT.
323 Molecular dynamics simulations showed that the V469L variant had a smaller pore radius and a
324 higher energetic barrier to ion transfer. The constriction was likely the result of hydrophobic
325 interactions between bulkier L469 residues causing part of the channel pore to become devoid
326 of water molecules^{62,63}.

327 The V471 variant is immediately adjacent to the PVP hinge motif and resulted in a >
328 50% increase in the peak current, with moderately slow deactivation, but a drastic negative shift
329 (~28mV). There was also an increase in protein expression to > 150% of WT and the pore
330 remained fully open in MD and the pore radius for the V471L variant of Kv3.2 channel was
331 slightly wider. An increased number of inter-subunit contacts made by V471L suggests a
332 possible mechanism how this mutant could selectively stabilize the open channel state. The
333 V469L and V471L variants had opposite loss-of-function and gain-of-function effects
334 respectively.

335 The lower current for V469L versus higher for V471L compared to WT could be
336 explained by the differences in protein expression levels. However, alterations in the protein
337 level would not cause changes in the kinetics of deactivation. The two variants could affect the
338 energy required for the protein to undergo conformational changes between the open and
339 closed states. The adjacency of the variants to the PVP motif would lead to changes to the
340 ability of the helix to kink at the hinge domain and facilitate channel gating. The V469L variant,
341 which results in the central hydrophobic valine of the PVP motif to be substituted by a bulkier
342 leucine extending into the pore, results in a lower tendency for the helix to kink, and therefore,
343 leads to slower channel gating and slower deactivation. In contrast, the stabilization of the
344 V471L channel in the "open" conformation, which would also affect channel gating, is consistent
345 with its moderately slow deactivation. Thus, our results indicate that the variants influence both
346 expression and channel function. However, our results do not identify the cause of the
347 differences in the expression levels of the two variants. It is likely that these result from
348 differences in protein folding or stability. Further studies, such as analysis of protein trafficking in
349 cells, are needed to identify the causes. For experimental simplicity, we carried out our *in vitro*
350 and *in silico* analyses with all four chains carrying the variant of interest. In the future, it would
351 be valuable to evaluate the spectrum of effects for channels carrying different combinations of
352 variant and WT chains; though, we anticipate similar effects.

353 We have not simulated the entire dynamics involved in channel activation and
354 deactivation. This process is too long to be studied by conventional MD methods. Enhanced MD
355 protocols, which aim at representing the free energy landscape of the molecular system by a set
356 of low-dimensional collective variables, have been used to simulate conformational changes for
357 some ion channel systems⁶⁴. These methods could be helpful for explaining the observed

358 changes in activation potential and deactivation time. However, no general protocol for deriving
359 a set of collective variables that capture the whole activation and deactivation cycle of Kv
360 channels like Kv3.2 is available yet.

361 The ability of the channel blocker 4-AP to inhibit the V469L Kv3.2 channel aligned with
362 the loss-of-function phenotype because 4-AP approaches the channel lumen from the
363 cytoplasm^{53,56,57}; therefore the steric hinderance of the pore cavity by V469L should not affect
364 its mechanism of action. Furthermore, the decreased ability of 4-AP to block the V471L channel
365 supports the gain-of-function hypothesis. Channel closing is destabilized in V471L, so 4-AP may
366 not bind as efficiently to the open channel. These results also illustrate how the personalized
367 structural biology approach can help evaluate the effects of possible pharmacological
368 interventions. For example, 4-AP is not likely to help individuals with the V469L variant, it is
369 possible that it could counteract some effects of the V471L variant.

370 Taken together, the clinical features of our UDN and the reported and the combined
371 experimental and molecular modeling of their *de novo* KCNC2 variants prove their functional
372 role as a cause of DEE. The phenotypes associated with the two variants in *KCNC2* are the
373 result of two fundamentally different molecular mechanisms, even though the residues are only
374 two amino acids away. Analyses of these variants in their structural context was key to revealing
375 their mechanistic and functional heterogeneity. In addition to the contribution to diagnosis, our
376 results also suggest that drugs that modulate the activity of Kv3.2 could be potential treatments.
377 This case study demonstrates the strength of personalized structural biology as a diagnostic
378 method to predict precise molecular hypotheses by taking the context of the variant if interest in
379 the 3D structure of the protein into account. Going forward, this approach has broad applicability
380 across VUS observed in studies from rare disease to cancer.

381

382 **METHODS**

383

384 *Structural modeling of Kv3.2*

385 The tetrameric structural model of human Kv3.2 (UniProtKB accession number: Q96PR1-1,
386 modeled residues: 1-484) was generated by homology modeling using the molecular modeling
387 software suite Rosetta (version 3.10)⁶⁵. The shaker family voltage dependent potassium
388 channel (Kv1.2-Kv2.1 paddle chimera channel) resolved to 2.4 Å (PDB ID: 2R9R) was used as
389 a template. The percent identity between the aligned positions of the sequences of Kv3.2 and
390 the template structure was 42.8%, sufficiently high for the chimera channel structure to serve as
391 a reliable template. A starting partial tetrameric model of Kv3.2, which only covered aligned
392 residues, was generated by threading the sequence of Kv3.2 onto the template structure using
393 the corresponding sequence alignment as a guide. Full models were created using the Rosetta
394 comparative modeling (RosettaCM) protocol⁶⁶ guided by the RosettaMembrane energy function
395⁶⁷ in a C4 symmetry mode⁶⁸. The boundaries of membrane-spanning segments were calculated
396 using the PPM server⁶⁹ based on the starting model. The boundaries were used to impose
397 membrane-specific Rosetta energy terms on residues within the theoretical membrane bilayer.
398 A total of 1000 full tetrameric models were generated using RosettaCM. The lowest-energy
399 model was selected as the final model for structure-based analysis in this work.

400

401 *MD system setup*

402 The Kv3.2 channel domain (residues L211 – M484) was embedded in a POPC (palmitoyl-
403 phosphatidylcholine) bilayer (~240 lipid molecules per leaflet) using the membrane builder tool
404 of CHARMM-GUI⁷⁰. The system was solvated in TIP3P water containing 0.15 M of neutralizing
405 KCl. Three K⁺ ions were placed in the channel selectivity filter at coordination sites S0, S2, and
406 S4 by inferring their positions from the crystal structure of the Kv1.2-2.1 chimeric channel (PDB:
407 2R9R)⁴³. Another K⁺ ion was placed below the selectivity filter in the aqueous channel cavity
408 (termed SCav site) and used for running umbrella simulations. During conventional MD
409 simulations, the position of the cavity K⁺ ion was constrained by imposing distance restraints to
410 the selectivity filter residue T437.

411

412 *Conventional MD simulations*

413 MD simulations of the Kv3.2 channel in POPC membranes were performed with AMBER16⁷¹
414 using the ff14SB force field for proteins⁷² and the Lipid17 force field. The system was simulated
415 in four replicas with a total simulation time of ~1 μ s. Bonds involving hydrogen atoms were
416 constrained with SHAKE⁷³. Nonbonded interactions were evaluated with a 10 Å cutoff, and
417 long-range electrostatic interactions were evaluated by the particle-mesh Ewald method⁷⁴.
418 Each MD system was first minimized using a four-step energy minimization procedure:
419 Minimization of only lipids was followed by minimization of only water + ions, and minimization
420 of protein before the whole system was minimized. With protein and ions restrained to their
421 initial coordinates, the lipid and water were heated to 50 K over 1000 steps with a step size of 1
422 fs in the NVT ensemble using Langevin dynamics with a rapid collision frequency of 10,000 ps⁻¹.
423 The system was then heated to 100 K over 50,000 steps with a collision frequency of 1000 ps⁻¹
424 and finally to 310 K over 200,000 steps and a collision frequency of 100 ps⁻¹. After changing to
425 the NPT ensemble, restraints on protein and ions were gradually removed over 500 ps. The
426 system was equilibrated for another 10 ns at 310 K with weak positional restraints (with a force
427 constant of 5 kcal mol⁻¹ Å⁻²) applied to protein C α atoms. The protein restraints were then
428 gradually removed over 20 ns, and production MD was conducted for 260 ns using a step size
429 of 2 fs, constant pressure periodic boundary conditions, anisotropic pressure scaling, and
430 Langevin dynamics.

431 Subsequent to running production MD, molecules were reimaged back into the
432 simulation box using CPPTRAJ⁷⁵ and the final 200 ns of each MD replica were analyzed. The
433 Kv3.2 channel was aligned to the first MD frame and the channel pore radius was measured
434 with HOLE⁷⁶ by taking conformations of Kv3.2 at every 1 ns.

435

436 *Umbrella MD simulations*

437 In order to estimate the free energy of K⁺ ion permeation through the cytosolic gate of Kv3.2
438 WT, V469L, and V471L channels, we calculated the potential of mean force (PMF) of moving a
439 K⁺ ion up the pore axis past the cytosolic constriction site and into the cavity below the
440 selectivity filter. The center of mass of the backbone atoms of the selectivity filter residues (T437
441 – Y440 of all four subunits) was defined as the origin of the pore axis. Umbrella potentials (with
442 a spring constant of 10 kcal mol⁻¹ Å⁻²) were placed at 0.5 Å intervals in the range from Z = -11 Å
443 (below selectivity filter) to Z = -44 Å (in cytosol), making a total of 67 umbrella simulations for
444 each 1D PMF. In addition, to ensure that the K⁺ ion remained in the vicinity of the pore axis
445 when it was no longer constrained by the S6 helices (i.e., was in bulk solvent), we used a

446 method described in Fowler et al.⁷⁷ and applied a flat-bottomed cylindrical constraint with a
447 radius of 8 Å and a spring constant of 10 kcal mol⁻¹ Å⁻². Starting configurations for each umbrella
448 window were prepared by taking the last frame from the conventional MD simulation and
449 gradually pulling the cavity K⁺ ion from SCav into cytosolic solvent over 10 ns using a spring
450 constant of 10 kcal mol⁻¹ Å⁻². To ensure that the direction of the pore axis was well-defined and
451 did not change during the simulation, the positions of the backbone atoms of the first two helix
452 turns of S6 (W448 – G454) were constrained by a harmonic potential with a force constant of 5
453 kcal mol⁻¹ Å⁻² during the pulling and umbrella simulations. Each umbrella simulation was run for
454 10 ns and repeated twice for each of the original four MD replicas. The WHAM method⁷⁸ as
455 implemented in the program by Grossfield⁷⁹ was used to remove the umbrella biases and
456 calculate 1D PMFs. A final 1D PMF was calculated for Kv3.2 WT, V469L, and V471L,
457 respectively, by averaging the individual PMFs for each variant, and the height of the free
458 energy barrier relative to the bulk solvent was measured.

459
460 *Heterologous expression of Kv3.2 ion channel and whole-cell voltage clamp electrophysiology*
461 Wild-type Kv3.2, V469L, and V471L channel plasmids (1 ng/μl for each plasmid) were
462 separately transfected with fluoresced green protein (GFP as marker to identify successful ion
463 channel expression) into Chinese Hamster Ovary (CHO) cells using 10 μl Fugene 6 (Promega),
464 following manufacturer's cell transfection instructions. Two days post transfection, cells with
465 green color were selected for patch clamp experiments.

466 Whole-cell voltage clamp experiments were performed at room temperature (22-23°C)
467 with 3~5 mΩ patch microelectrodes, by using a MultiClamp 700B amplifier and DigiData 1550B
468 low-noise data acquisition system (Molecular Devices Inc., Sunnydale, California). The
469 extracellular solution contained (in mmol/L) NaCl 145, KCl 4.0, MgCl₂ 1.0, CaCl₂ 1.8, glucose
470 10, and HEPES 10; the pH was 7.4, adjusted with NaOH. The pipette (intracellular) solution
471 contained (in mmol/L) KCl 110, MgCl₂ 1.0, ATP-K₂ 5.0, BAPTA-K4 5.0, and HEPES 10; the pH
472 was 7.2, adjusted with KOH. Data acquisition was performed using pClamp 10.7 software
473 (Molecular Devices Inc.), sampling at 1 kHz and low-pass-filtered at 5 kHz. Activating current
474 was elicited with 1-second depolarizing pulses from a holding potential of -80 mV at a 10-mV
475 increments, and tail current was recorded on return to -40 mV. The voltage-clamp protocol is
476 shown in Figure EP. Pulses were delivered every 15 seconds. The current-voltage (I-V)
477 relationships were analyzed by fitting the Boltzmann equation to the data:

478 $I = I_{\max} / \{1 + \exp [(V_t - V_{0.5}) / k]\}$, where I_{\max} is the maximal current, V_t is the test potential, $V_{0.5}$ is
479 the membrane potential at which 50% of the channels are activated, and k is the slope factor.
480 Current densities (pA/pF) were obtained after normalization to cell surface area calculated by
481 the Membrane Test in pClamp 10.7. A potassium channel blocker 4-aminopyridine (4-AP at 200
482 μM; Sigma-Aldrich Co., St. Louis, MO, USA) was used to test the sensitivity of wildtype Kv3.2
483 and two variant (V469L and V471L) channels to drug block by 1-second repetitive pulsing
484 protocol from a holding potential of -80 mV to a testing potential of +60 mV (Figure S3).

485
486 *DNA constructs for WT and variants of KCNC2*

487 The coding sequences DNA of human *Homo sapiens* potassium voltage-gated channel
488 subfamily C member 2 *KCNC2* (NM_139137.4) was subcloned into pcDNA3.1+ /C-(k)-DYK
489 expression vector with an equipped Flag tag (DYKDDDDK) in C-terminal (GenScript, NJ, USA).

490 The mutant KCNC2 variants Kv3.2-V469L and Kv3.2-V471L cDNA constructs were generated
491 by using a pair of designed overlapping primers for the PCR in the QuikChange Site-Directed
492 Mutagenesis Kit (Agilent USA Cat. # 200523) and by PCR Overlap Extension method to
493 introduce the mutation site in. Both variants were confirmed by DNA sequencing.

494

495 *Western Blot*

496 To detect the Kv3.2 protein expression and to perform protein functional analysis, the wild type
497 and two mutated cDNA plasmids were transfected to CHO stable cells (ATCC, USA) by X-
498 tremeGENE 9 DNA Transfection Reagent (Roche). The transfected cells were collected and
499 lysed in modified Radio-Immunoprecipitation Assay (RIPA) lysis buffer (50 mM Tris pH = 7.4,
500 150mM NaCl, 1% NP-40, 0.2% Sodium Deoxycholate, 1mM EDTA), and 1% protease inhibitor
501 cocktail (Sigma-Aldrich Co., USA). Collected protein samples were subjected to gel
502 electrophoresis using 4–12% BisTris NuPAGE precast gels (Invitrogen Life Technologies, USA)
503 and transferred to PVDF-FL membranes (MilliporeSigma, USA). Primary antibody against Flag
504 epitope tag located on FLAG fusion proteins (Sigma-Aldrich, polyclonal ANTI-FLAG, rabbit host.
505 F7425) was used to detect the Kv3.2 protein by indirect immunofluorescent staining at a 1:500
506 dilution. Anti-Na⁺/K⁺ ATPase antibody (Developmental Studies Hybridoma Bank, Antibodies at
507 the University of Iowa for use in research, USA) at a 1:1000 dilution was used as an internal
508 quality control. IRDye conjugated secondary anti-rabbit antibody (LI-COR Biosciences Inc. USA)
509 was used at a 1:10000 dilution. The membranes were scanned using the Odyssey Infrared
510 Imaging System, and the integrated density value of bands was determined using the Odyssey
511 Image Studio software (LI-COR Biosciences Inc. USA).

512

513 *Clinical Report*

514 Please contact the corresponding authors for clinical details.

515

516 **ACKNOWLEDGEMENTS**

517 First, we thank all affected UDN individuals and their families. We thank members of the Capra,
518 Meiler, and UDN Labs for helpful comments. This work was conducted in part with the
519 resources of the Advanced Computing Center for Research and Education at Vanderbilt
520 University, Nashville, TN.

521

522 **FUNDING**

523 This work was supported by awards from The National Institutes of Health (NIH) Common Fund,
524 through the Office of Strategic Coordination and the Office of the NIH Director, to the clinical
525 sites (U01HG007674 to Vanderbilt University Medical Center, U01HG010215-03S1 to
526 Washington University). The work was also supported by NIH awards R01LM013434, and
527 R01GM126249. BL was supported by a fellowship from the American Heart Association.

528

529 **AUTHOR CONTRIBUTIONS**

530 Conceptualization, S.M., T.A.C., G.K., J.A.P.III, J.A.C.; Methodology, S.M., B.L., N.H., T.Y.,
531 W.S., R.L.M., D.M.R., J.M., G.K., J.A.P.III, J.A.C.; Investigation, S.M., B.L., N.H., T.Y., W.S.,
532 J.H.S., C.W.M., G.K.; Writing – Original Draft, S.M., T.A.C., B.L., G.K., N.H., T.Y.; Writing –
533 Review & Editing, S.M., B.L., G.K., J.M., J.A.P.III, G.K., J.A.C; Funding Acquisition, R.H.,
534 R.L.M., D.M.R., UDN, J.A.P.III, J.M., J.A.C.; Resources, J.D.C., R.H., J.H.N., R.L.M., D.M.R.,
535 J.M., J.A.P.III, J.A.C.; Supervision, D.C.R., R.L.M., D.M.R., J.M., G.K., J.A.P.III, J.A.C.

536


537 **CONSORTIUM**

538 Undiagnosed Diseases Network:

539 Maria T Acosta, David R Adams, Pankaj Agrawal, Mercedes E Alejandro, Patrick Allard,
540 Justin Alvey, Ashley Andrews, Euan A Ashley, Mahshid S Azamian, Carlos A Bacino, Guney
541 Bademci, Eva Baker, Ashok Balasubramanyam, Dustin Baldrige, Jim Bale, Deborah Barbouth,
542 Gabriel F Batzli, Pinar Bayrak-Toydemir, Alan H Beggs, Gill Bejerano, Hugo J Bellen, Jonathan
543 A Bernstein, Gerard T Berry, Anna Bican, David P Bick, Camille L Birch, Stephanie Bivona,
544 John Bohnsack, Carsten Bonnenmann, Devon Bonner, Braden E Boone, Bret L Bostwick,
545 Lorenzo Botto, Lauren C Briere, Elly Brokamp, Donna M Brown, Matthew Brush, Elizabeth A
546 Burke, Lindsay C Burrage, Manish J Butte, John Carey, Olveen Carrasquillo, Ta Chen Peter
547 Chang, Hsiao-Tuan Chao, Gary D Clark, Terra R Coakley, Laurel A Cobban, F Sessions Cole,
548 Heather A Colley, Cynthia M Cooper, Heidi Cope, William J Craigen, Precilla D'Souza, Surendra
549 Dasari, Mariska Davids, Jyoti G Dayal, Esteban C Dell'Angelica, Shweta U Dhar, Naghmeh
550 Dorrani, Daniel C Dorset, Emilie D Douine, David D Draper, Laura Duncan, David J Eckstein,
551 Lisa T Emrick, Christine M Eng, Cecilia Esteves, Tyra Estwick, Liliana Fernandez, Carlos
552 Ferreira, Elizabeth L Fieg, Paul G Fisher, Brent L Fogel, Irman Forghani, Laure Fresard, William
553 A Gahl, Rena A Godfrey, Alica M Goldman, David B Goldstein, Jean-Philippe F Gourdine, Alana
554 Grajewski, Catherine A Groden, Andrea L Gropman, Melissa Haendel, Neil A Hanchard,
555 Nichole Hayes, Frances High, Ingrid A Holm, Jason Hom, Yong Huang, Alden Huang, Rosario
556 Isasi, Fariha Jamal, Yong-Hui Jiang, Jean M Johnston, Angela L Jones, Lefkothea Karaviti,
557 Emily G Kelley, Dana Kiley, David M Koeller, Isaac S Kohane, Jennefer N Kohler, Susan
558 Korrick, Mary E Koziura, Deborah Krakow, Donna M Krasnewich, Joel B Krier, Jennifer E Kyle,
559 Seema R Lalani, Byron Lam, Brendan C Lanpher, Ian R Lanza, C Christopher Lau, Pace Laura,
560 Jozef Lazar, Kimberly LeBlanc, Brendan H Lee, Hane Lee, Roy Levitt, Shawn E Levy, Richard
561 A Lewis, Sharyn A Lincoln, Pengfei Liu, Xue Zhong Liu, Nicola Longo, Sandra K Loo, Joseph
562 Loscalzo, Richard L Maas, Calum A MacRae, Ellen F Macnamara, Valerie V Maduro, Marta M
563 Majcherska, May Christine V Malicdan, Laura A Mamounas, Teri A Manolio, Rong Mao,
564 Thomas C Markello, Ronit Marom, Gabor Marth, Beth A Martin, Martin G Martin, Julian A
565 Martínez-Agosto, Shruti Marwaha, Thomas May, Jacob McCauley, Allyn McConkie-Rosell,
566 Colleen E McCormack, Alexa T McCray, Thomas O Metz, Matthew Might, Eva Morava-Kozicz,
567 Paolo M Moretti, Marie Morimoto, John J Mulvihill, David R Murdock, Avi Nath, Stanley F
568 Nelson, J Scott Newberry, Sarah K Nicholas, Donna Novacic, Devin Oglesbee, James P
569 Orengo, Stephen Pak, J Carl Pallais, Christina G S Palmer, Moretti Paolo, Jeanette C Papp,
570 Neil H Parker, Jennifer E Posey, John H Postlethwait, Lorraine Potocki, Barbara N Pusey,
571 Aaron Quinlan, Archana N Raja, Genecee Renteria, Chloe M Reuter, Lynette C Rives, Amy K
572 Robertson, Lance H Rodan, Jill A Rosenfeld, Robb K Rowley, Maura Ruzhnikov, Ralph Sacco,
573 Jacinda B Sampson, Susan L Samson, Mario Saporta, Judy Schaechter, Timothy Schedl, Kelly
574 Schoch, Daryl A Scott, Lisa Shakachite, Prashant Sharma, Vandana Shashi, Kathleen Shields,
575 Jimann Shin, Rebecca H Signer, Catherine H Sillari, Edwin K Silverman, Janet S Sinsheimer,
576 Kathy Sisco, Kevin S Smith, Lilianna Solnica-Krezel, Rebecca C Spillmann, Joan M Stoler,
577 Nicholas Stong, Jennifer A Sullivan, Shirley Sutton, David A Sweetser, Holly K Tabor, Cecelia P
578 Tamburro, Queenie K-G Tan, Mustafa Tekin, Fred Telischi, Willa Thorson, Cynthia J Tiftt,
579 Camilo Toro, Alyssa A Tran, Tiina K Urv, Matt Velinder, Dave Viskochil, Tiphannie P Vogel,
580 Colleen E Wahl, Melissa Walker, Nicole M Walley, Chris A Walsh, Jennifer Wambach, Jijun
581 Wan, Lee-Kai Wang, Michael F Wangler, Patricia A Ward, Katrina M Waters, Bobbie-Jo M
582 Webb-Robertson, Daniel Wegner, Monte Westerfield, Matthew T Wheeler, Anastasia L Wise,
583 Lynne A Wolfe, Jeremy D Woods, Elizabeth A Worthey, Shinya Yamamoto, John Yang,
584 Amanda J Yoon, Guoyun Yu, Diane B Zastrow, Chunli Zhao, Stephan Zuchner.

585

586 FIGURES
587




588
589

590 **Figure 1: Candidate pathogenic variants in *KCNC2* are nearby, but have different**
591 **structural contexts in Kv3.2.**

592 **(A)** Homo-tetrameric structure of Kv3.2. The complete structural model of Kv3.2 (*KCNC2*) was
593 generated using RosettaCM from Kv1.2-Kv2.1 paddle chimera channel (PDB ID: 2R9R, 42.8%
594 sequence identity). Four homologous subunits form the tetrameric channel pore structure; chain
595 A is shown in color. Each monomeric subunit has intracellular N terminal domain (black) and six
596 transmembrane helical domains. S1-S4 form the voltage sensing domain (VSD, beige). The S4-
597 S5 linker (magenta) is the force transducer between the VSD and the channel pore, formed by

598 the S5 (yellow) and the S6 (red) helices. The S5-S6 linker (orange) acts as the selectivity filter,
599 allowing only potassium ions through the channel. The patient variant (V469L) is located in the
600 PVP motif (purple; residues 468-470) which acts a hinge domain facilitating channel gating. The
601 previously discovered variant (V471L) suspected to also cause DEE-like symptoms is located
602 adjacent to the PVP motif. **(B)** A view of the carbon backbone of the S6 helix, showing the PVP
603 hinge region. The valines at positions 469 (blue) and 471 (green) are shown. **(C)** A view of the
604 channel pore formed by the tetrameric structure of Kv3.2, showing the selectivity filter (orange)
605 and the hinge domain (purple). **(D)** A closer view of the channel pore with reference amino acids
606 valine at positions 469 (deep blue) and 471 (teal) shown, alongside variant leucine residues
607 (light blue and cyan). Residue 469 extends into the pore, while residue 471 faces away from the
608 pore. **(E)** A view of the carbon backbone of the native (valine) and substituted (leucine) amino
609 acids at positions 469 and 471.
610
611

612



613

614

Figure 2: Candidate Kv3.2 variants cause loss and gain of channel function.

615

616

617

618

619

620

621

622

623

624

625

626

627

628

629


630

631

632

633

(A) Representative potassium current traces for wild type (WT) Kv3.2 in CHO cells recorded by voltage clamp. WT shows the characteristic current amplitude and fast deactivation (short deactivating tail currents). (B) Current traces for the V469L variant show lower peak current and very slow deactivation. (C) Current traces for the V471L variant demonstrate much higher current and moderately slowed deactivation compared to WT. Each voltage clamp used the protocol shown in the insert of panel A. The deactivation tails are compared in greater detail in **Figure S2A-C**. (D) Current vs. steady-state voltage (I-V) curves for WT Kv3.2, V469L, and V471L. The V469L variant showed a much lower current at steady-state, while the V471L variant showed increased current at steady-state. (E) Current vs. voltage plots for the tails for each variant. V469L has a slight negative shift (~10 mV), while V471L has a large negative voltage shift (~28 mV). Each group considered 6 to 10 cells. (F) Percentage of channel activity (steady-state current) blocked by 200 μ M 4-aminopyridine (4-AP), a known voltage gated potassium channel blocker, for WT, V469L, and V471L. The WT and V469L Kv3.2 were similarly blocked ($p > 0.05$, $n=6$ for each), but V471L was resistant to 4-AP blockage ($p < 0.0001$, $n=6$). **Figure S3A-C** shows the protocol and representative traces for each variant. Altogether, these data demonstrate loss- and gain-of-function effects on channel activity for V469L and V471L, respectively.




634
635

636 **FIGURE 3: Candidate *KCNC2* variants modify Kv3.2 expression levels.**

637 **(A)** Western blot showing expression of WT Kv3.2, V469L and V471L variants in CHO stable
638 cells. The mock well shows only the ATPase antibody tag, while the WT, V469L and V471L
639 labeled wells have the corresponding version of Kv3.2 loaded. Kv3.2 has a molecular weight of
640 ~70 kDa and shows up as one band, below the 75 kD marker, thus confirming the presence of
641 the protein in its native state. The V471L band is larger and more intense than WT, while V469L
642 is faint. This suggests higher protein levels for V471L and lower levels for V469L compared to
643 WT. **(B)** Protein expression estimated from Western blot band intensity. The protein levels for
644 V469L were roughly half that of the WT, and the proteins levels for the V471L were more than
645 one and a half times that of WT. These results support a loss-of-function phenotype for V469L
646 and a potential gain-of-function phenotype for V471L.

647
648
649




650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665

FIGURE 4: The channel pore of Kv3.2 V469L becomes constricted in MD simulations whereas the pore of V471L adopts a stable open conformation.

(A) – (C) Snapshots from MD simulations of Kv3.2 WT, V469L, and V471L. The entire MD trajectories are shown in **Videos V1-V6**. For each protein, the channel-membrane system was simulated in four replicas with a total simulation time of more than 1 μ s. The protein is represented as ribbon with each chain shown in a different color. One domain in the front is not shown to better see the channel cavity. The amino acids at positions 469 and 471 are depicted as spheres and colored cyan and yellow, respectively. Water molecules are shown as sticks (red-white). (D) Surface representation of the pore radius of Kv3.2 WT (left) and 1D pore radius profiles (right) along the channel axis (z-axis) for WT, V469L, and V471L. The solid line and shaded area represent the average radius and standard deviation from four independent MD replicas.

666
667



668
669
670

671 **FIGURE 5: V469L increases the energy required for K⁺ ion transfer through the cytosolic**
672 **gate of Kv3.2 compared to WT and V471L.**


673 **(A)** We estimated the energy required to transfer a K⁺ ion (purple sphere) through the cytosolic
674 channel gate, from the bulk solvent into the cavity below the selectivity filter by umbrella MD
675 simulation. A close-up view of the gate and aqueous cavity of WT Kv3.2 channel is shown. The
676 subunit in the front is not depicted to better see the K⁺ permeation pathway which is lined by
677 residues on S6. The side chains of reference amino acids V469, P470, and V471 are drawn as
678 cyan, green, and yellow spheres, respectively. **(B)** 1D PMF of K⁺ transfer through the channel
679 for Kv3.2 WT, V469L, and V471L. The solid line and shaded area represent the average PMF
680 and standard deviation of four independent MD simulations. The V469L variant induces a
681 greater energetic barrier to ion transfer compared to WT and V471L. The increased energetic
682 requirement is focused on the conserved P470 residue in the hinge region. This supports the
683 relevance of the disruption of this element to function and the functional difference between
684 V469L and V471L in spite of their spatial proximity.

685

686 **SUPPLEMENTARY FIGURES**

687

688



689

690


691 **FIGURE S1: KCNC2 variants are located in the evolutionarily conserved hinge domain**
692 **and predicted to be deleterious.**

693 **(A)** The amino acid sequence flanking the PVP motif (green box) and the V469L and V471L are
694 deeply conserved across vertebrate species. **(B)** V469L and V471L are both predicted to be
695 functional by the combined annotation dependent depletion (CADD) and genomic evolutionary
696 rating profile (GERP) scores.

697

698

699



700

701


702 **FIGURE S2: Candidate *KCNC2* variants have different effects on Kv3.2 deactivation tail**
703 **kinetics.**

704 **(A)** Current traces for the deactivating tails for wild type (WT) Kv3.2. The short peak indicates
705 fast deactivation, which is a hallmark of Kv3.2, and required for fast depolarization of membrane
706 potential in the central nervous system. **(B)** Current traces for the deactivating tails of V469L
707 Kv3.2 show a much slower deactivation, indicated by the long peak which does not return to
708 zero. **(C)** Current traces for the deactivating tails of V471L Kv3.2 demonstrate a much higher
709 current and a somewhat slowed deactivation, indicated by the higher and longer peak,
710 compared to the WT.

711

712

713




714

715

716 **FIGURE S3: 4-AP differentially blocks variant Kv3.2 channels.**

717 The effect of 4-aminopyridine (4-AP), a voltage gated potassium channel blocker, on WT Kv3.2
718 (A), V469L (B), and V471L (C) channel activity. Representative baseline (absence of 4-AP)
719 current traces are shown in black for each protein, and representative traces with 200 μM 4-AP
720 are shown in gray. 4-AP blocked the WT and V469L at similar levels. However, activity of the
721 V471L variant was only modestly reduced by 4-AP and maintained high activity. The voltage-
722 clamp protocol is shown as insert in panel A.

723



724
725
726
727
728
729
730

FIGURE S4: Distribution of ϕ and ψ backbone angles of pore helix residues 461 to 478 sampled in MD simulation of Kv3.2 WT, V469L, and V471L.

For Kv3.2 V469L variant, small changes are found at ψ 466, ϕ 467, ψ 468 and ϕ 469, and for Kv3.2 V471L at ψ 466 (TABLE T1)

Residue	Dihedral	WT	V469L	V71L	WT - V469L	WT - V471L	V469L - V471L
		median	median	median			
463	ϕ	-68.214	-67.374	-67.786	0.840	0.428	0.412
	ψ	-32.987	-35.295	-37.187	2.308	4.2	1.892
464	ϕ	-65.619	-64.638	-64.060	0.981	1.559	0.578
	ψ	-36.610	-38.107	-37.833	1.497	1.223	0.274
465	ϕ	-78.080	-76.485	-76.110	1.595	1.97	0.375
	ψ	-32.992	-34.092	-36.759	1.100	3.767	2.667
466	ϕ	-69.493	-72.195	-71.071	2.702	1.578	1.124
	ψ	-21.215	-27.900	-28.040	6.685	6.825	0.140
467	ϕ	-78.686	-72.731	-75.937	5.955	2.749	3.206
	ψ	-54.420	-51.163	-53.854	3.257	0.566	2.691
468	ϕ	-76.931	-77.422	-80.585	0.491	3.654	3.163
	ψ	-32.838	-21.468	-30.719	11.370	2.119	9.251
469	ϕ	-62.922	-58.835	-61.602	4.087	1.32	2.767
	ψ	-43.718	-43.248	-41.395	0.470	2.323	1.853
470	ϕ	-58.551	-60.526	-57.736	1.975	0.815	1.160
	ψ	-31.664	-31.793	-28.719	0.129	2.945	2.816
471	ϕ	-70.613	-71.664	-68.606	1.051	2.007	0.956
	ψ	-40.992	-41.250	-39.090	0.258	1.902	1.644
472	ϕ	-63.507	-63.709	-68.455	0.202	4.948	4.746
	ψ	-43.176	-45.512	-41.865	2.336	1.311	1.025
473	ϕ	-63.365	-64.722	-63.215	1.357	0.15	1.207
	ψ	-38.527	-38.229	-38.088	0.298	0.439	0.141
474	ϕ	-65.186	-65.446	-63.958	0.260	1.228	0.968
	ψ	-36.940	-38.138	-38.796	1.198	1.856	0.658
475	ϕ	-70.334	-67.447	-67.946	2.887	2.388	0.499
	ψ	-46.164	-45.022	-44.724	1.142	1.44	0.298


731

732

733 **TABLE T1: Summary of ϕ and ψ backbone angles of pore helix residues 463 to 475**
734 **sampled in MD simulation of Kv3.2 WT, V469L, and V471L.**

735 For Kv3.2 V469L variant, small changes are found at ψ and ϕ angles for several residues. The
736 alterations for ψ 466 were consistent between both the variants, indicating a strain on the S6
737 helix resulting from both variants. However, the difference between V469L and WT for ψ 468
738 and ϕ 469 were specific for V469L variant, and not observed for the V471L variant. Conversely,
739 the alterations to ψ 471 and ϕ 472 were observed specifically for the V471L variant, indicating
740 these changes were specific for the position and resulting amino acid of the variants.

741



742

743

744 **FIGURE S5: Adjacent pore helices in Kv3.2 form a contact between residues 471 and 480.**

745 **(A)** Cytosolic view of structural models of Kv3.2 WT and V471L. Each subunit is shown with a

746 different color. V471 in WT Kv3.2 and L471 in the pV471L variant, respectively, are represented

747 as spheres and colored yellow. Residue Y480 is shown in cyan. **(B)** Close-up view of residues

748 V471 (left) or L471 (right) interacting with Y480.

749

750 REFERENCES

- 751 1. Ng, S.B., Turner, E.H., Robertson, P.D., Flygare, S.D., Bigham, A.W., Lee, C., Shaffer, T.,
752 Wong, M., Bhattacharjee, A., Eichler, E.E., et al. (2009). Targeted capture and massively
753 parallel sequencing of 12 human exomes. *Nature* *461*, 272–276.
- 754 2. Ionita-Laza, I., Makarov, V., Yoon, S., Raby, B., Buxbaum, J., Nicolae, D.L., and Lin, X.
755 (2011). ARTICLE Finding Disease Variants in Mendelian Disorders By Using Sequence Data:
756 Methods and Applications. *Am. J. Hum. Genet.* *89*, 701–712.
- 757 3. Ng, S.B., Buckingham, K.J., Lee, C., Bigham, A.W., Tabor, H.K., Dent, K.M., Huff, C.D.,
758 Shannon, P.T., Jabs, E.W., Nickerson, D.A., et al. (2010). Exome sequencing identifies the
759 cause of a mendelian disorder. *Nat. Genet.* *42*, 30–35.
- 760 4. Boycott, K.M., Rath, A., Chong, J.X., Hartley, T., Alkuraya, F.S., Baynam, G., Brookes, A.J.,
761 Brudno, M., Carracedo, A., Den Dunnen, J.T., et al. (2017). COMMENTARY International
762 Cooperation to Enable the Diagnosis of All Rare Genetic Diseases.
- 763 5. Chong, J.X., Buckingham, K.J., Jhangiani, S.N., Boehm, C., Sobreira, N., Smith, J.D., Harrell,
764 T.M., Mcmillin, M.J., Wiszniewski, W., Gambin, T., et al. (2015). The Genetic Basis of Mendelian
765 Phenotypes: Discoveries, Challenges, and Opportunities.
- 766 6. Boycott, K.M., Hartley, T., Biesecker, L.G., Gibbs, R.A., Innes, A.M., Riess, O., Belmont, J.,
767 Dunwoodie, S.L., Jojic, N., Lassmann, T., et al. (2019). A Diagnosis for All Rare Genetic
768 Diseases: The Horizon and the Next Frontiers. *Cell* *177*, 32–37.
- 769 7. Gahl, W.A., Mulvihill, J.J., Toro, C., Markello, T.C., Wise, A.L., Ramoni, R.B., Adams, D.R.,
770 and Tift, C.J. (2016). The NIH Undiagnosed Diseases Program and Network: Applications to
771 modern medicine. *Mol. Genet. Metab.* *117*, 393–400.
- 772 8. Gahl, W.A., Wise, A.L., and Ashley, E.A. (2015). The Undiagnosed Diseases Network of the
773 National Institutes of Health. *JAMA* *314*, 1797.
- 774 9. Ramoni, R.B., Mulvihill, J.J., Adams, D.R., Allard, P., Ashley, E.A., Bernstein, J.A., Gahl,
775 W.A., Hamid, R., Loscalzo, J., McCray, A.T., et al. (2017). The Undiagnosed Diseases Network:
776 Accelerating Discovery about Health and Disease. *Am. J. Hum. Genet.* *100*, 185–192.
- 777 10. Niroula, A., and Vihinen, M. (2016). Variation Interpretation Predictors: Principles, Types,
778 Performance, and Choice (John Wiley and Sons Inc.).
- 779 11. Tang, H., and Thomas, P.D. (2016). Tools for predicting the functional impact of
780 nonsynonymous genetic variation. *Genetics* *203*, 635–647.
- 781 12. Peterson, T.A., Doughty, E., and Kann, M.G. (2013). Towards precision medicine: Advances
782 in computational approaches for the analysis of human variants. *J. Mol. Biol.* *425*, 4047–4063.
- 783 13. Thusberg, J., Olatubosun, A., and Vihinen, M. (2011). Performance of mutation
784 pathogenicity prediction methods on missense variants. *Hum. Mutat.* *32*, 358–368.
- 785 14. Niroula, A., and Vihinen, M. (2017). Predicting Severity of Disease-Causing Variants. *Hum.*
786 *Mutat.* *38*, 357–364.
- 787 15. Riera, C., Padilla, N., and de la Cruz, X. (2016). The Complementarity Between Protein-
788 Specific and General Pathogenicity Predictors for Amino Acid Substitutions. *Hum. Mutat.* *37*,
789 1013–1024.
- 790 16. Grimm, D.G., Azencott, C.A., Aicheler, F., Gieraths, U., Macarthur, D.G., Samocha, K.E.,
791 Cooper, D.N., Stenson, P.D., Daly, M.J., Smoller, J.W., et al. (2015). The evaluation of tools
792 used to predict the impact of missense variants is hindered by two types of circularity. *Hum.*
793 *Mutat.* *36*, 513–523.
- 794 17. Vihinen, M. (2021). Functional effects of protein variants. *Biochimie* *180*, 104–120.
- 795 18. Niroula, A., and Vihinen, M. (2019). How good are pathogenicity predictors in detecting
796 benign variants? *PLoS Comput. Biol.* *15*,.
- 797 19. Delsuc, M., Vitorino, M., and Kieffer, B. (2020). Determination of Protein Structure and
798 Dynamics by NMR. In *Structural Biology in Drug Discovery*, (Wiley), pp. 295–323.
- 799 20. Lyumkis, D. (2019). Challenges and opportunities in cryo-EM single-particle analysis. *J. Biol.*
800 *Chem.* *294*, 5181–5197.

- 801 21. Murata, K., and Wolf, M. (2018). Cryo-electron microscopy for structural analysis of dynamic
802 biological macromolecules. *Biochim. Biophys. Acta - Gen. Subj.* 1862, 324–334.
- 803 22. Herzik, M.A., Wu, M., and Lander, G.C. (2019). High-resolution structure determination of
804 sub-100 kDa complexes using conventional cryo-EM. *Nat. Commun.* 10, 1–9.
- 805 23. Gauto, D.F., Estrozi, L.F., Schwieters, C.D., Effantin, G., Macek, P., Sounier, R., Sivertsen,
806 A.C., Schmidt, E., Kerfah, R., Mas, G., et al. (2019). Integrated NMR and cryo-EM atomic-
807 resolution structure determination of a half-megadalton enzyme complex. *Nat. Commun.* 10, 1–
808 12.
- 809 24. Ikeya, T., Güntert, P., and Ito, Y. (2019). Protein structure determination in living cells. *Int. J.*
810 *Mol. Sci.* 20,.
- 811 25. Senior, A.W., Evans, R., Jumper, J., Kirkpatrick, J., Sifre, L., Green, T., Qin, C., Žídek, A.,
812 Nelson, A.W.R., Bridgland, A., et al. (2020). Improved protein structure prediction using
813 potentials from deep learning. *Nature* 577, 706–710.
- 814 26. Kuhlman, B., and Bradley, P. (2019). Advances in protein structure prediction and design.
815 *Nat. Rev. Mol. Cell Biol.* 20, 681–697.
- 816 27. Gao, W., Mahajan, S.P., Sulam, J., and Gray, J.J. (2020). Deep Learning in Protein
817 Structural Modeling and Design. *Patterns* 1, 100142.
- 818 28. Waterhouse, A., Bertoni, M., Bienert, S., Studer, G., Tauriello, G., Gumienny, R., Heer, F.T.,
819 De Beer, T.A.P., Rempfer, C., Bordoli, L., et al. (2018). SWISS-MODEL: Homology modelling of
820 protein structures and complexes. *Nucleic Acids Res.* 46, W296–W303.
- 821 29. Vetri, L., Cali, F., Vinci, M., Amato, C., Roccella, M., Granata, T., Freri, E., Solazzi, R.,
822 Romano, V., and Elia, M. (2020). A de novo heterozygous mutation in KCNC2 gene implicated
823 in severe developmental and epileptic encephalopathy. *Eur. J. Med. Genet.* 63, 103848.
- 824 30. Berg, A.T., Levy, S.R., and Testa, F.M. (2018). Evolution and course of early life
825 developmental encephalopathic epilepsies: Focus on Lennox-Gastaut syndrome. *Epilepsia* 59,
826 2096–2105.
- 827 31. Berg, A.T., Mahida, S., and Poduri, A. (2021). KCNQ2-DEE: developmental or epileptic
828 encephalopathy? *Ann. Clin. Transl. Neurol.* 8, 666–676.
- 829 32. McTague, A., Howell, K.B., Cross, J.H., Kurian, M.A., and Scheffer, I.E. (2016). The genetic
830 landscape of the epileptic encephalopathies of infancy and childhood. *Lancet Neurol.* 15, 304–
831 316.
- 832 33. Claes, L., Del-Favero, J., Ceulemans, B., Lagae, L., Van Broeckhoven, C., and De Jonghe,
833 P. (2001). De novo mutations in the sodium-channel gene SCN1A cause severe myoclonic
834 epilepsy of infancy. *Am. J. Hum. Genet.* 68, 1327–1332.
- 835 34. Allen, N.M., Weckhuysen, S., Gorman, K., King, M.D., and Lerche, H. (2020). Genetic
836 potassium channel-associated epilepsies: Clinical review of the Kv family. *Eur. J. Paediatr.*
837 *Neurol.* 24, 105–116.
- 838 35. Rudy, B., and McBain, C.J. (2001). Kv3 channels: Voltage-gated K⁺ channels designed for
839 high-frequency repetitive firing. *Trends Neurosci.* 24, 517–526.
- 840 36. MacKinnon, R. (1995). Pore loops: An emerging theme in ion channel structure. *Neuron* 14,
841 889–892.
- 842 37. Hidalgo, P., and MacKinnon, R. (1995). Revealing the architecture of a K⁺ channel pore
843 through mutant cycles with a peptide inhibitor. *Science (80-)*. 268, 307–310.
- 844 38. Pascual, J.M., Shieh, C.C., Kirsch, G.E., and Brown, A.M. (1995). Multiple residues specify
845 external tetraethylammonium blockade in voltage-gated potassium channels. *Biophys. J.* 69,
846 428–434.
- 847 39. Kim, D.M., and Nimigean, C.M. (2016). Voltage-gated potassium channels: A structural
848 examination of selectivity and gating. *Cold Spring Harb. Perspect. Biol.* 8, a029231.
- 849 40. Pongs, O. (1993). Shaker related K channels. *Semin. Neurosci.* 5, 93–100.
- 850 41. Yarov-Yarovoy, V., Baker, D., and Catterall, W.A. (2006). Voltage sensor conformations in
851 the open and closed states in ROSETTA structural models of K channels.

- 852 42. Long, S.B., Campbell, E.B., and MacKinnon, R. (2005). Voltage sensor of Kv1.2: Structural
853 basis of electromechanical coupling. *Science* (80-.). 309, 903–908.
- 854 43. Long, S.B., Tao, X., Campbell, E.B., and MacKinnon, R. (2007). Atomic structure of a
855 voltage-dependent K⁺ channel in a lipid membrane-like environment. *Nature* 450, 376–382.
- 856 44. Park, J., Koko, M., Hedrich, U.B.S., Hermann, A., Cremer, K., Haberlandt, E., Grimm, M.,
857 Alhaddad, B., Beck-Woedl, S., Harrer, M., et al. (2019). KCNC1-related disorders: new de novo
858 variants expand the phenotypic spectrum. *Ann. Clin. Transl. Neurol.* 6, 1319–1326.
- 859 45. Waters, M.F., Minassian, N.A., Stevanin, G., Figueroa, K.P., Bannister, J.P.A., Nolte, D.,
860 Mock, A.F., Evidente, V.G.H., Fee, D.B., Müller, U., et al. (2006). Mutations in voltage-gated
861 potassium channel KCNC3 cause degenerative and developmental central nervous system
862 phenotypes. *Nat. Genet.* 38, 447–451.
- 863 46. Muona, M., Berkovic, S.F., Dibbens, L.M., Oliver, K.L., Maljevic, S., Bayly, M.A., Joensuu,
864 T., Canafoglia, L., Franceschetti, S., Michelucci, R., et al. (2015). A recurrent de novo mutation
865 in KCNC1 causes progressive myoclonus epilepsy. *Nat. Genet.* 47, 39–46.
- 866 47. Rademacher, A., Schwarz, N., Seiffert, S., Pendziwiat, M., Rohr, A., Van Baalen, A., Helbig,
867 I., Weber, Y., and Muhle, H. (2020). Whole-exome sequencing in NF1-related west syndrome
868 leads to the identification of KCNC2 as a novel candidate gene for epilepsy. *Neuropediatrics* 51,
869 368–372.
- 870 48. Schwarz, N., Seiffert, S., Pendziwiat, M., Rademacher, A., Hedrich, U.B., Augustijn, P.B.,
871 Baier, H., Bayat, A., Bisulli, F., Buono, R.J., et al. (2021). Karl Martin Klein 19-21 , Ioanna
872 Kousiappa 22 , Wolfram S. 7 Kunz 23 , Holger Lerche 1 , Laura Licchetta 9. *Lejla*
873 *Mulahasanovic* 12, 20.
- 874 49. Leaver-Fay, A., Tyka, M., Lewis, S.M., Lange, O.F., Thompson, J., Jacak, R., Kaufman, K.,
875 Renfrew, P.D., Smith, C.A., Sheffler, W., et al. (2011). Rosetta3: An object-oriented software
876 suite for the simulation and design of macromolecules. In *Methods in Enzymology*, pp. 545–574.
- 877 50. Imbrici, P., Grottesi, A., D'Adamo, M.C., Mannucci, R., Tucker, S.J., and Pessia, M. (2009).
878 Contribution of the central hydrophobic residue in the PXP motif of voltage-dependent K⁺
879 channels to S6 flexibility and gating properties. *Channels* 3, 39–45.
- 880 51. Rudy, B., Chow, A., Lau, D., Amarillo, Y., Ozaita, A., Saganich, M., Moreno, H., Nadal, M.S.,
881 Hernandez-Pineda, R., Hernandez-Cruz, A., et al. (1999). Contributions of Kv3 channels to
882 neuronal excitability. In *Annals of the New York Academy of Sciences*, (New York Academy of
883 Sciences), pp. 304–343.
- 884 52. Erisir, A., Lau, D., Rudy, B., and Leonard, C.S. (1999). Function of specific K⁺ channels in
885 sustained high-frequency firing of fast-spiking neocortical interneurons. *J. Neurophysiol.* 82,
886 2476–2489.
- 887 53. Kirsch, G.E., and Drewe, J.A. (1993). Gating-dependent mechanism of 4-aminopyridine
888 block in two related potassium channels. *J. Gen. Physiol.* 102, 797–816.
- 889 54. Alviña, K., and Khodakhah, K. (2010). The therapeutic mode of action of 4-aminopyridine in
890 cerebellar ataxia. *J. Neurosci.* 30, 7258–7268.
- 891 55. Chang, K.W., Yuan, T.C., Fang, K.P., Yang, F.S., Liu, C.J., Chang, C.S., and Lin, S.C.
892 (2003). The increase of voltage-gated potassium channel Kv3.4 mRNA expression in oral
893 squamous cell carcinoma. *J. Oral Pathol. Med.* 32, 606–611.
- 894 56. Armstrong, C.M., and Loboda, A. (2001). A model for 4-aminopyridine action on K channels:
895 Similarities to tetraethylammonium ion action. *Biophys. J.* 81, 895–904.
- 896 57. Choquet, D., and Korn, H. (1992). Mechanism of 4-Aminopyridine Action on Voltage-gated
897 Potassium Channels in Lymphocytes.
- 898 58. Van Hoeymissen, E., Held, K., Freitas, A.C.N., Janssens, A., Voets, T., and Vriens, J.
899 (2020). Gain of channel function and modified gating properties in TRPM3 mutants causing
900 intellectual disability and epilepsy. *Elife* 9, 1–12.
- 901 59. Crawford, K., Xian, J., Helbig, K.L., Galer, P.D., Parthasarathy, S., Lewis-Smith, D.,
902 Kaufman, M.C., Fitch, E., Ganesan, S., O'Brien, M., et al. (2021). Computational analysis of

- 903 10,860 phenotypic annotations in individuals with SCN2A-related disorders. *Genet. Med.* 23,
904 1263–1272.
- 905 60. Kaczmarek, L.K., and Zhang, Y. (2017). Kv3 channels: Enablers of rapid firing,
906 neurotransmitter release, and neuronal endurance. *Physiol. Rev.* 97, 1431–1468.
- 907 61. Labro, A.J., Raes, A.L., Bellens, I., Ottschytch, N., and Snyders, D.J. (2003). Gating of
908 Shaker-type Channels Requires the Flexibility of S6 Caused by Prolines. *J. Biol. Chem.* 278,
909 50724–50731.
- 910 62. Yazdani, M., Jia, Z., and Chen, J. (2020). Hydrophobic dewetting in gating and regulation of
911 transmembrane protein ion channels. *J. Chem. Phys.* 153, 110901.
- 912 63. Aryal, P., Sansom, M.S.P., and Tucker, S.J. (2015). Hydrophobic gating in ion channels. *J.*
913 *Mol. Biol.* 427, 121–130.
- 914 64. Lev, B., Murail, S., Poitevin, F., Cromer, B.A., Baaden, M., Delarue, M., and Allen, T.W.
915 (2017). String method solution of the gating pathways for a pentameric ligand-gated ion
916 channel. *Proc. Natl. Acad. Sci. U. S. A.* 114, E4158–E4167.
- 917 65. Lemam, J.K., Weitzner, B.D., Lewis, S.M., Adolf-Bryfogle, J., Alam, N., Alford, R.F.,
918 Aprahamian, M., Baker, D., Barlow, K.A., Barth, P., et al. (2020). Macromolecular modeling and
919 design in Rosetta: recent methods and frameworks. *Nat. Methods* 17, 665–680.
- 920 66. Song, Y., Dimaio, F., Wang, R.Y.R., Kim, D., Miles, C., Brunette, T., Thompson, J., and
921 Baker, D. (2013). High-resolution comparative modeling with RosettaCM. *Structure* 21, 1735–
922 1742.
- 923 67. Barth, P., Wallner, B., and Baker, D. (2009). Prediction of membrane protein structures with
924 complex topologies using limited constraints. *Proc. Natl. Acad. Sci. U. S. A.* 106, 1409–1414.
- 925 68. DiMaio, F., Leaver-Fay, A., Bradley, P., Baker, D., and André, I. (2011). Modeling symmetric
926 Macromolecular structures in Rosetta3. *PLoS One* 6, 20450.
- 927 69. Lomize, M.A., Pogozheva, I.D., Joo, H., Mosberg, H.I., and Lomize, A.L. (2012). OPM
928 database and PPM web server: Resources for positioning of proteins in membranes. *Nucleic*
929 *Acids Res.* 40,.
- 930 70. Wu, E.L., Cheng, X., Jo, S., Rui, H., Song, K.C., Dávila-Contreras, E.M., Qi, Y., Lee, J.,
931 Monje-Galvan, V., Venable, R.M., et al. (2014). CHARMM-GUI membrane builder toward
932 realistic biological membrane simulations. *J. Comput. Chem.* 35, 1997–2004.
- 933 71. Case, D.A., Betz, R.M., Cerutti, D.S., Cheatham III, T.E., Darden, T.A., Duke, R.E., Giese,
934 T.J., Gohlke, H., Goetz, A.W., Homeyer, N., et al. (2016). Principal contributors to the current
935 codes : Amber 2016 Reference Manual. AMBER 2016, Univ. California, San Fr.
- 936 72. Maier, J.A., Martinez, C., Kasavajhala, K., Wickstrom, L., Hauser, K.E., and Simmerling, C.
937 (2015). ff14SB: Improving the Accuracy of Protein Side Chain and Backbone Parameters from
938 ff99SB. *J. Chem. Theory Comput.* 11, 3696–3713.
- 939 73. Ryckaert, J.-P., Ciccotti, G., and Berendsen, H.J.C. (1977). Numerical integration of the
940 Cartesian Equations of Motion of a System with Constraints: Molecular Dynamics of n-Alkanes.
941 *J. Comput. Phys.* 23, 321–341.
- 942 74. Darden, T., York, D., and Pedersen, L. (1993). Particle mesh Ewald: An N·log(N) method for
943 Ewald sums in large systems. *J. Chem. Phys.* 98, 10089–10092.
- 944 75. Roe, D.R., and Cheatham, T.E. (2013). PTRAJ and CPPTRAJ: Software for processing and
945 analysis of molecular dynamics trajectory data. *J. Chem. Theory Comput.* 9, 3084–3095.
- 946 76. Smart, O.S., Neduvellil, J.G., Wang, X., Wallace, B.A., and Sansom, M.S.P. (1996). HOLE:
947 A program for the analysis of the pore dimensions of ion channel structural models. *J. Mol.*
948 *Graph.* 14, 354–360.
- 949 77. Fowler, P.W., and Sansom, M.S.P. (2013). The pore of voltage-gated potassium ion
950 channels is strained when closed. *Nat. Commun.* 4, 1–8.
- 951 78. Kumar, S., Rosenberg, J.M., Bouzida, D., Swendsen, R.H., and Kollman, P.A. (1992). THE
952 weighted histogram analysis method for free-energy calculations on biomolecules. I. The
953 method. *J. Comput. Chem.* 13, 1011–1021.

954 79. Grossfield, A. WHAM: the weighted histogram analysis method.
955